|
注册号: Registration number: |
ChiCTR2600116450 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-09 16:58:36 |
|
注册时间: Date of Registration: |
2026-01-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
苯磺酸瑞马唑仑全麻诱导-维持方案的围术期安全性评估:基于多中心真实世界数据的术中知晓发生率的研究 |
|
Public title: |
Perioperative Safety Evaluation of a Remimazolam Besylate Induction-Maintenance General Anesthesia Regimen :A Multicenter,Real-World Study on the Incidence of Intraoperative Awareness |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
苯磺酸瑞马唑仑全麻诱导-维持方案的围术期安全性评估:基于多中心真实世界数据的术中知晓发生率的研究 |
|
Scientific title: |
Perioperative Safety Evaluation of a Remimazolam Besylate Induction-Maintenance General Anesthesia Regimen :A Multicenter,Real-World Study on the Incidence of Intraoperative Awareness |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郑惠芳 |
研究负责人: |
张先杰 |
|
Applicant: |
Zheng Huifang |
Study leader: |
Zhang Xianjie |
|
申请注册联系人电话: Applicant telephone: |
+86 188 5044 1895 |
研究负责人电话:
Study leader's |
+86 139 8108 8319 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2549937101@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zxianjiemazui@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国四川省德阳市旌阳区太行山路399号 |
研究负责人通讯地址: |
中国四川省德阳市旌阳区太行山路399号 |
|
Applicant address: |
No. 399 Taihangshan Road, Jingyang District, Deyang City, Sichuan Province, China |
Study leader's address: |
No. 399 Taihangshan Road, Jingyang District, Deyang City, Sichuan Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
618099 |
研究负责人邮政编码: Study leader's postcode: |
618099 |
|
申请人所在单位: |
成都医学院 |
||
|
Applicant's institution: |
Chengdu Medical College |
||
|
研究负责人所在单位: |
德阳市人民医院 |
||
|
Affiliation of the Leader: |
Deyang People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-04-135-K01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
德阳市人民医院伦理委员会审查批件 |
||
|
Name of the ethic committee: |
Review Reply from the Ethics Committee of Deyang People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-14 00:00:00 | ||
|
伦理委员会联系人: |
赵小军 |
||
|
Contact Name of the ethic committee: |
Zhao Xiaojun |
||
|
伦理委员会联系地址: |
中国四川省德阳市旌阳区太行山路399号 |
||
|
Contact Address of the ethic committee: |
No. 399 Taihangshan Road, Jingyang District, Deyang City, Sichuan Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 838 259 1211 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
德阳市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Deyang People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国四川省德阳市旌阳区太行山路399号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 399 Taihangshan Road, Jingyang District, Deyang City, Sichuan Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
四川省医学科技创新研究会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sichuan Provincial Society for Medical Science and Technology Innovation |
||||||||||||||||||||||
|
研究疾病: |
术中知晓 |
||||||||||||||||||||||
|
Target disease: |
Awareness with recall |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
核心目标:量化瑞马唑仑全麻方案在真实世界临床实践中的术中知晓发生率,建立安全性基准。 次要目标:评估瑞马唑仑术后24小时恶心呕吐发生率及严重程度(无、轻度、中重度),为优化全麻镇静-镇痛方案、提升患者术后康复质量提供循证依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary Objective: Quantify the incidence of intraoperative awareness in the general anesthesia regimen with remimazolam in real-world clinical practice, and establish a safety benchmark. Secondary Objectives: Evaluate the incidence and severity (none, mild, moderate-severe) of postoperative nausea and vomiting within 24 hours after remimazolam administration, so as to provide evidence-based support for optimizing the sedation-analgesia regimen of general anesthesia and improving the quality of patients' postoperative recovery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 妊娠或哺乳期女性(尿妊娠试验阳性); 2. 对瑞马唑仑或阿片类药物(如瑞芬太尼)过敏者; 3. 重症肌无力、肌营养不良症或其他影响神经肌肉传导的疾病; 4. 存在精神疾病史(如精神分裂症、双相障碍); 5. 严重器官功能障碍:肝功能不全(Child-Pugh C级);肾功能不全(eGFR <= 30 mL/min/1.73m^2);未控制的心力衰竭(NYHA分级Ⅲ-Ⅳ级); 6. 其他禁忌症:研究者判断存在全身麻醉高风险或不宜参与研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Pregnant or lactating women (with a positive urine pregnancy test); 2.Patients with a history of allergy to remimazolam or opioid drugs (e.g., remifentanil); 3.Patients with myasthenia gravis, muscular dystrophy, or other diseases that affect neuromuscular transmission; 4.Patients with a history of mental illness (e.g., schizophrenia, bipolar disorder); 5.Patients with severe organ dysfunction: hepatic insufficiency (Child-Pugh Class C); renal insufficiency (eGFR < 30 mL/min/1.73m^2); uncontrolled heart failure (NYHA Class Ⅲ–Ⅳ); 6.Other contraindications: patients judged by the investigator to be at high risk for general anesthesia or otherwise unsuitable for participation in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-15 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-15 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过合理的要求联系项目负责人获得 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Obtain by contacting the project manager with a legitimate request |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例报告表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |